Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34656227

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Nov
First author
Fennell DA

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):e13. doi: 10.1016/S1470-2045(21)00702-6.
    note
    Source null
    related pmid
    34973223
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1.
    note
    Source null
    related pmid
    34973224
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2025 May;26(5):e238. doi: 10.1016/S1470-2045(25)00221-9.
    note
    Source null
    related pmid
    40318655
    relationship
    Erratum in

Authors and identifiers

  1. name
    Fennell DA
    type
    Author
  2. name
    Ewings S
    type
    Author
  3. name
    Ottensmeier C
    type
    Author
  4. name
    Califano R
    type
    Author
  5. name
    Hanna GG
    type
    Author
  6. name
    Hill K
    type
    Author
  7. name
    Danson S
    type
    Author
  8. name
    Steele N
    type
    Author
  9. name
    Nye M
    type
    Author
  10. name
    Johnson L
    type
    Author
  11. name
    Lord J
    type
    Author
  12. name
    Middleton C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Fennell DA
    type
    Author
  2. name
    Ewings S
    type
    Author
  3. name
    Ottensmeier C
    type
    Author
  4. name
    Califano R
    type
    Author
  5. name
    Hanna GG
    type
    Author
  6. name
    Hill K
    type
    Author
  7. name
    Danson S
    type
    Author
  8. name
    Steele N
    type
    Author
  9. name
    Nye M
    type
    Author
  10. name
    Johnson L
    type
    Author
  11. name
    Lord J
    type
    Author
  12. name
    Middleton C
    type
    Author
bibliography ids
  1. nci-bib-65d15d3e9988f4f21be98580
book metadata
content sha256
17450a378fb031e33409d8af3b145f7598ac5210aae9aae30f716c8c7b8e7cd6
document type
citation
dois
  1. 10.1016/S1470-2045(21)00471-X
electronic publication date
display
2021 Oct 14
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34656227
immutable id
pubmed:34656227@17450a378fb031e33409d8af3b145f7598ac5210aae9aae30f716c8c7b8e7cd6
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1530-1540
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jan;23(1):e13. doi: 10.1016/S1470-2045(21)00702-6.
    note
    Source null
    related pmid
    34973223
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1.
    note
    Source null
    related pmid
    34973224
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2025 May;26(5):e238. doi: 10.1016/S1470-2045(25)00221-9.
    note
    Source null
    related pmid
    40318655
    relationship
    Erratum in
outcomes validated
false
pmid
34656227
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
7e234c02e2ed2c867435c3e7fef18aa646ba4a6fc93131e7a1f71e371fcc97a0
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Nov
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34656227/
title
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.

Preserved source evidence · Not medical advice